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52Objectives: The primary analysis estimated the cost-effectiveness of transfemoral transcatheter aortic valve im-
plantation (Edwards SAPIEN heart valve; Edwards Lifesciences LLC, Irvine, Calif) compared with standard
management in inoperable patients with severe, symptomatic aortic stenosis. The secondary analysis estimated
the cost-effectiveness of transcatheter aortic valve implantation (transfemoral or transapical approaches)
(SAPIEN heart valve) compared with surgical aortic valve replacement in operable patients with severe, symp-
tomatic aortic stenosis.
Methods:A combined decision tree andMarkovmodel was developed to compare costs, life-years, and quality-
adjusted life-years over a 20-year time horizon from the Canadian health-care payer perspective. The Placement
of Aortic Transcatheter Valves trial provided rates of postoperative complications and mortality. Costs were de-
rived from the Ontario Case Costing Initiative. Comprehensive sensitivity analyses were used to explore the im-
pact of uncertainty on the cost-effective estimates.
Results: In the primary analysis, comparing transfemoral transcatheter aortic valve implantation and standard
management resulted in incremental cost-effectiveness ratios of $36,458/life-year and $51,324/quality-adjusted
life-year. In the secondary analysis, transcatheter aortic valve implantation (transfemoral or transapical) and sur-
gical aortic valve replacement were compared, resulting in an incremental cost-effectiveness ratio of $870,143/
life-year and transcatheter aortic valve implantation being dominated by surgical aortic valve replacement when
comparing quality-adjusted life-years. Deterministic sensitivity analysis for the primary analysis identified the
procedural costs and 1-year mortality rates of both transfemoral transcatheter aortic valve implantation and stan-
dard management to be the most sensitive parameters in the model, whereas results from the secondary analysis
were largely unchanged. Removal of long-term complications in both analyses led to more favorable incremen-
tal cost-effectiveness ratios for transcatheter aortic valve implantation.
Conclusions: This economic evaluation suggested that transfemoral transcatheter aortic valve implantation was
a cost-effective option compared with standard management for inoperable patients with severe, symptomatic
aortic stenosis, but it might not be a cost-effective treatment compared with surgical aortic valve replacement for
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The Journal of Thoracic and Cardiovascular SurgerySupplemental material is available online.Aortic stenosis (AS) is a common valvular heart disease
characterized by the narrowing or constriction of the aortic
valve.1 Approximately 300,000 patients have severe AS in
the United States, with approximately 60,000 of these pa-
tients undergoing aortic valve replacement each year.2 As
the population continues to age, these numbers are expected
to increase.
Patients managed with only medical therapy or percuta-
neous aortic balloon valvuloplasty have a poor prognosis,
and therefore this treatment is now used only as a bridge
to more invasive therapy or for palliative care.2c July 2013
Abbreviations and Acronyms
AKI ¼ acute kidney injury
AS ¼ aortic stenosis
CI ¼ confidence interval
DSA ¼ deterministic sensitivity analysis
ICER ¼ incremental cost-effectiveness ratio
LY ¼ life-year
MI ¼ myocardial infarction
NYHA ¼ New York Heart Association
OCCI ¼ Ontario Case Costing Initiative
PARTNER ¼ Placement of Aortic Transcatheter
Valves
PSA ¼ probabilistic sensitivity analysis
QALY ¼ quality-adjusted life-year
SAVR ¼ surgical aortic valve replacement
SM ¼ standard management
SSAS ¼ severe symptomatic aortic stenosis
TA ¼ transapical
TAVI ¼ transcatheter aortic valve
implantation
TF ¼ transfemoral
WTP ¼ willingness to pay
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DThe standard of care for patients with severe AS is an in-
vasive procedure known as ‘‘surgical aortic valve replace-
ment’’ (SAVR). Operative mortality in octogenarians and
high-risk patients was high, ranging from 5% to 11%,3,4
and because of the invasiveness of the procedure many
potential candidates refused surgery or were denied
surgery.5 These patients were usually considered at an
increased surgical risk because of 1 or a combination of
the following characteristics: age greater than 75 years, sig-
nificant comorbidities, European System for Cardiac Oper-
ative Risk Evaluation greater than 20%, or Society of
Thoracic Surgeons risk score greater than 10%.5 This has
led to the development of less-invasive approaches, such
as transcatheter aortic valve implantation (TAVI), to provide
high-risk patients with a suitable alternative to open surgery.
TAVI is preformed mainly via 2 different approaches: the
‘‘retrograde’’ (transfemoral [TF]) approach and a more in-
vasive approach known as ‘‘transapical’’ (TA), which is
used in patients with poor vascular access.6
The results of the Placement of Aortic Transcatheter
Valves (PARTNER US, cohorts A and B) randomized clin-
ical trial have recently been published.5,7 Cohort B
randomized patients who were unable to undergo SAVR
to TF-TAVI or standard management (SM) and showed
TF-TAVI to have a significant impact on mortality
(P<.001).5 Cohort A randomized patients with a high op-
erative risk to TAVI (TF or TA) or SAVR and showed TAVI
to be noninferior in terms of mortality (P<.001).7 Despite
the promising clinical evidence collected in the PARTNERThe Journal of Thoracic and Ctrial, estimates of cost-effectiveness from the Canadian per-
spective are not currently available.
The primary objective of the present study was to esti-
mate the cost-effectiveness of TF-TAVI compared with
SM in inoperable patients with severe symptomatic aortic
stenosis (SSAS). A secondary analysis was conducted to es-
timate the cost-effectiveness of TAVI (TF or TA) compared
with SAVR in operable patients with SSAS.MATERIALS AND METHODS
Overview
From a third-party Canadian payer’s perspective, an economic model
was developed to estimate the expected costs and outcomesmeasured using
life-years (LYs) and quality-adjusted life-years (QALYs) associated with 4
treatment options (ie, TF-TAVI, SM, TAVI [TF or TA], and SAVR) for pa-
tients with SSAS over a 20-year time horizon.Model Structure
The model is composed of a decision tree for a 30-day postoperative
phase and a Markov model for a long-term phase (ie, day 31 to 20 years).
The structures of the short-term and long-term models are shown in
Figure 1, A and B, respectively. During the 30-day postoperative phase, pa-
tients were at risk of operative death and postoperative complications, in-
cluding other acute complications (eg, endocarditis, major vascular
complications, paravalvular leaks, pacemaker implantation, major bleed-
ing, and atrial fibrillation), stroke, myocardial infarction (MI), acute kidney
injury (AKI), or reoperation. In addition, patients receiving TAVI or SM
might require a SAVR. The 30-day model estimated the expected costs
of the index hospitalization along with expected LYs and QALYs over
30 days for the 4 treatments.
The long-term costs and effects beyond 30 days after the surgery
were estimated using a Markov model. Patients surviving a postoperative
complication in the short-term model entered the long-term model in
their respective post-event health state. Patients surviving other acute
complications or experiencing no complications in the short-term model
entered the ‘‘alive without complications’’ health state in the long-term
model. Three postoperative complications, including stroke, MI, and
AKI, were included in the long-term model. The model estimates
were on a yearly basis (so termed a ‘‘yearly Markov cycle’’) on which
the costs and effects were calculated at the end of each year. Then pa-
tients transitioned among these health states according to their characteris-
tics, and the calculations were started over again. Because of the
unavailability of the long-term data, it was assumed that patients with
stroke or MI, or receiving dialysis will stay in these post-events health
states until they died.Clinical Parameters
Overview. The clinical data used for the economic model primarily
came from cohorts A and B of the PARTNER randomized controlled trial5,7
and were supplemented by a targeted literature search that identified any
relevant studies on TAVI, SM, and SAVR. Important data and sources for
the models are listed in Tables 1 and E1 and briefly summarized next.
Mortality. Cumulative 30-day postoperative mortality was derived
from PARTNER cohorts B and A for the primary and secondary analyses,
respectively.5,7 The 1-year mortality for all 4 treatments was based on the
respective cumulative mortality reported in the PARTNER cohorts at 1
year; however, to avoid double counting, the number of patients dying at
30 days was subtracted from both the numerator and the denominator of
the cumulative rate. Because of a lack of relevant long-term mortality
data for both inoperable and operable patient populations, the mortalityardiovascular Surgery c Volume 146, Number 1 53
FIGURE 1. A, Structure of 30-day postoperative decision tree. B, Structure of long-term Markov model. SAVR, Surgical aortic valve replacement.
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Drates for years 2 to 20 were based on the 2007 Canadian life tables.8 To
match the average age of the PARTNER cohorts, the model used a starting
age of 83 and 84 years for the primary and secondary analyses,
respectively.
Clinical events. The majority of 30-day postoperative complication
rates were derived from the PARTNER trial data.5,7 The rates of
temporary and permanent dialysis were assumed to be the same for all 4
treatments and derived from an individual source.9 One-year event rates
for stroke, MI, and AKI in all 4 treatments were also derived from the re-
spective cohorts of the PARTNER trial.5,7 Because no long-term evidence
is available, these rates were assumed to remain constant over the 20-year
time horizon.
Costs. This economic evaluation was conducted from the perspective of
a third-party Canadian health-care payer. Relevant costs included proce-
dural cost of index hospitalization, cost of complications, prescription
costs, and costs associated with long-term health states, including costs
of rehospitalization and long-term care facility stays. Costs were mainly
derived from the administrative database, Ontario Case Costing Initiative
(OCCI).10 Costs were discounted at 5% annually and presented in 2010
Canadian dollars.
Procedural cost of index hospitalization. Procedural cost for
TAVI included initial evaluation and testing costs, hospital and supply
costs,11 and the allocated $37,606 for the cost of the Edwards SAPIEN
valve (Edwards Lifesciences LLC, Irvine, Calif).12 Procedural costs
for SM included testing costs, hospital and supply costs, and the
cost of the balloon catheter.13 The procedural costs for SAVR were
obtained from the OCCI for ‘‘cardiac valve repair except percutaneous
transluminal approach’’ CMG Grouper 165 in patients aged 70þ
years.10
Costs of medications. Patients surviving TF or TA commonly re-
ceive clopidogrel (75 mg/d) for 6 months for a total cost of $472,14,15
whereas warfarin therapy (5.58 mg/d) is recommended in patients
surviving SAVR for a total annual cost of $162.14,16,17 Patients with54 The Journal of Thoracic and Cardiovascular Surgechronic heart failure receive a variety of different medications, resulting
in a total yearly cost of $642 for the SM treatment arm.14,18
Quality-adjusted life years. QALYs have been used as a generic
effect measure in economic evaluation because they capture treatment ef-
fect on both quantity and quality of life. In a model-based economic evalu-
ation, QALYs are calculated by multiplying the time duration of a patient
staying in a health statewith the quality weight for that health state. Quality
weights are typically measured using health utility. The present study used
the baseline health utilities by New York Heart Association (NYHA) func-
tional class estimated by Gohler and colleagues.19 Differences in the pro-
portion of patients in each NYHA functional class between the respective
comparators were based on data from the 2 cohorts of the PARTNER trial
and carried forward for all 4 treatments for years 2 to 20 of the model.5,7
Base-case and uncertainty analyses. The best available point
estimates from existing evidence (eg, mean value) were used in the base-
case analyses in which incremental cost-effectiveness ratios (ICERs)
were the summary measure. By definition, ICER, a measure of efficiency
in health economic evaluation, is the ratio of the difference in cost between
treatments to the difference in effect between the same treatments. The
higher the ICER, the less cost-effective will be the new treatment (assum-
ing new treatment is compared with old treatment).
Because model-based economic evaluation incorporates data from a va-
riety of sources, uncertainty from data inputs is an important issue that
needs to be appropriately and sufficiently handled. Extensive sensitivity
and scenario analyses were conducted to assess the impact of uncertainty
on the cost-effectiveness results.
Specifically, 1-way deterministic sensitivity analyses (DSAs) were per-
formed to assess the impact of varying the model parameters over a range
of values based on their respective 95% confidence intervals (CIs).
Scenario analyses were used to determine the impact of various model
assumptions, including different mortality rates beyond the PARTNER trial
follow-up, the exclusion of long-term complications (stroke, MI, and AKI)
in the model beyond 1 year, and the use of a shorter time horizon for the
model.ry c July 2013
TABLE 1. Procedural, 30-day postoperative, and long-term model inputs (mean [a, b])
Model variable
Inoperable patients Operable patients
TF-TAVI Reference SM Reference TF or TA-TAVI Reference SAVR Reference
Postoperative complications (all beta distributions)
Postoperative death 0.0503 (9, 170) 5 0.0279 (5, 174) 5 0.0345 (12, 336) 7 0.0627 (22, 329) 7
Reoperation 0.0168 (3, 176) 5 0.0112 (2, 177) 5 0.0144 (5, 343) 7 0.0972 (7, 65) 7
Conversion to SAVR 0 5 0.0168 (3, 176) 5 0.0144 (5, 343) 7 N/A N/A
Endocarditis 0 5 0 5 0 7 0.0028 (1, 350) 7
Vascular complications 0.162 (29, 150) 5 0.0112 (2, 177) 5 0.109 (38, 310) 7 0.0313 (11, 340) 7
Pacemaker implantation 0.0335 (6, 173) 5 0.0503 (9, 170) 5 0.0374 (13, 335) 7 0.0342 (12, 339) 7
Major bleeding 0.168 (30, 149) 5 0.0391 (7, 172) 5 0.0920 (32, 316) 7 0.191 (67, 284) 7
Atrial fibrillation 0.006 (1, 178) 5 0.0112 (2, 177) 5 0.0862 (30, 318) 7 0.160 (56, 295) 7
Stroke 0.0670 (12, 167) 5 0.0168 (3, 176) 5 0.0460 (16, 332) 7 0.0228 (8, 343) 7
Permanent disability 0.75 (9, 3) 5 0.667 (2, 1) 5 0.813 (13, 3) 7 0.875 (7, 1) 7
MI 0 5 0 5 0 7 0.0057 (2, 349) 7
AKI 0.112 (2177) 5 0.0223 (4, 175) 5 0.0402 (14, 334) 7 0.0399 (14, 337) 7
Temporary dialysis 0.267 (4, 11) 9
Permanent dialysis 0.067 (1, 14) 9
Late event probabilities (all beta distributions)
Stroke 0.101 (18, 161) 5 0.0447 (8, 171) 5 0.0575 (20, 328) 7 0.0285 (10, 341) 7
MI 0.0056 (1, 178) 5 0.0056 (1, 178) 5 0.0029 (1, 347) 7 0.0057 (2, 349) 7
AKI 0.0279 (5, 174) 5 0.0615 (11, 168) 5 0.0862 (30, 318) 7 0.0798 (28, 323) 7
Mortality
1 y 0.271 (46, 124) 5 0.483 (84, 90) 5 0.214 (72, 264) 7 0.204 (67, 262) 7
2 y Life table 8 Life table 8 Life table 8 Life table 8
3þ y Life table 8 Life table 8 Life table 8 Life table 8
Procedural cost of index hospitalization and pharmacotherapy (all gamma distributions)
Procedural costs 45,865 (16, 2867) 11,12 29,600 (46, 643) 13 45,865 (16, 2867) 11,12 32,784 (352, 93) 10
Cost of general ward stay 365 (16, 23) 11
Cost of pharmacotherapy 472 (16, 29)* 14,15 642 (16, 40)y 14,18 472 (16, 29)* 14,15 162 (16, 10)z 14,16,17
TF-TAVI, Transfemoral transcatheter aortic valve implantation; SM, standard management; TA-TAVI, transapical transcatheter aortic valve implantation; SAVR, surgical aortic
valve replacement; N/A, not applicable; MI, myocardial infarction; AKI, acute kidney injury. *Patients undergoing TAVI receive pharmacotherapy for only 6 months after op-
eration. yYearly pharmacotherapy cost for SM. zYearly pharmacotherapy cost for SAVR.
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DUnlikeDSAs that use predeterminedvalues in themodel calculation, prob-
abilistic sensitivity analysis (PSA) specifies a distribution for a parameter and
randomly draws a value from that distribution and calculates the result using
the model.20 PSA has an advantage of adequately reflecting sample uncer-
tainty around parameters of interest. PSAwas conducted to take into account
all uncertain parameters simultaneously (in contrast with DSA in which only
1 parameter was considered at a time). Decision uncertainty was expressed as
cost-effectiveness acceptability curves, which present the probability that
a treatment option is more cost-effective than its comparators as a function
of maximum willingness to pay (WTP) for the outcome of interest.
Model validation. The model was constructed in Microsoft Excel
2007 (Microsoft Corp, Redmond, Wash) and replicated in TreeAge Pro
Suite 2009 (TreeAge Software Inc, Williamstown, Mass). The results
were compared and confirmed to be identical.RESULTS
Base-Case Results: Primary Analysis (Inoperable
Patients)
Over the 20-year time horizon, the expected costs of TF-
TAVI and SM were $88,991 and $57,963, respectively. The
TF-TAVI treatment arm was estimated to produce 0.85 and
0.60 more LYs and QALYs, respectively, compared with
SM. Comparing TF-TAVI with SM resulted in ICERs of
$36,458/LY and $51,324/QALY, respectively.The Journal of Thoracic and CBase-Case Results: Secondary Analysis (Operable
Patients)
The expected costs of TAVI (TF or TA) and SAVR were
$85,755 and $74,602, respectively, over the 20-year time
horizon. The incremental LY gained when comparing
TAVI with SAVR was 0.0128, resulting in an ICER of
$870,143/LY. In contrast, TAVI was dominated by SAVR
because it produced 0.102 less QALYs at higher costs.
Deterministic Sensitivity Analyses
Differences in cost-effectiveness results based on a num-
ber of 1-way DSAs are presented in Figure 2, A and B, for
the primary analysis. The model was most sensitive to the
procedural costs and 1-year mortality rates for both treat-
ments. The rates of paravalvular leaks and 30-day mortality
for the TF-TAVI treatment were also sensitive to change.
DSA for the secondary analysis was also conducted (results
not shown, available on request). The model was robust to
changes in all parameters because the ICERs for the LYs
comparison remained high (ie, >$200,000/LY), and
SAVR remained dominant to TAVI when QALYs were
used to measure benefits. Of note, the ICER of TAVI versusardiovascular Surgery c Volume 146, Number 1 55
FIGURE 2. A, DSA for TF-TAVI versus SM (LYs). B, DSA for TF-TAVI versus SM (QALYs). TF-TAVI, Transfemoral transcatheter aortic valve implan-
tation; SM, standard management; LY, life-year; QALY, quality-adjusted life-year; Can$, Canadian dollars; SAVR, surgical aortic valve replacement; ICER,
incremental cost-effectiveness ratio.
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DSAVRwould be reduced to $111,249/QALYwhen using the
lower CI for the cost of the TAVI procedure.Scenario Analyses
Key modeling assumptions were tested in scenario anal-
yses and are presented in Table 2 for the primary and sec-
ondary analyses. Altering the long-term (2 years)
mortality rates for the treatments, while holding all other
base-case assumptions constant, had a marginal effect on
the ICERs for the primary analysis. Removing the long-
term (2 years) complications of stroke, MI, and AKI
from the primary analysis resulted in more favorable ICERs56 The Journal of Thoracic and Cardiovascular Surgefor TAVI. The conclusion from the secondary analysis re-
mained unchanged when altering long-term mortality rates
and exclusion of long-term complications. Shortening the
model time horizon to 10 years resulted in slightly larger
ICERs for all comparisons and scenarios tested.Probabilistic Sensitivity Analysis
When comparing TF-TAVI with SM in inoperable pa-
tients, the probability of TF-TAVI being cost-effective
was 0.727 and 0.441 at a WTP threshold of $49,000 per
LY/QALY, respectively (Figure 3, A and B). When compar-
ing TAVI (TF or TA) with SAVR in operable patients, thery c July 2013
TABLE 2. Scenario analyses for primary and secondary analyses
Scenario analyses for TF-TAVI vs SM
Mortality beyond 1 y
Life table mortality for both TF-TAVI
and SM (base case)
Apply SM mortality (0.50) for
both TF-TAVI and SM
Apply treatment specific mortality
for TF-TAVI (0.31) and SM (0.50)
Holding other base-case assumptions
constant
$36,458/LY
$51,324/QALY
$57,356/LY
$81,837/QALY
$36,326/LY
$53,184/QALY
No new cases of stroke, MI, or AKI
beyond 1 y
$28,585/LY
$32,157/QALY
$60,059/LY
$78,866/QALY
$34,823/LY
$45,761/QALY
10-y time horizon while holding other
base-case assumptions constant
$38,713/LY
$52,953/QALY
$59,666/LY
$83,446/QALY
$37,537/LY
$54,032/QALY
No new cases of stroke, MI, or AKI
beyond 1 y, with 10-y time horizon
$31,830/LY
$35,903/QALY
$61,911/LY
$79,941/QALY
$35,617/LY
$46,366/QALY
Scenario analyses for TAVI (TF or TA) vs SAVR
Mortality beyond 1 y
Life table mortality for both TAVI
and SAVR (base case)
Apply SAVR mortality (0.25) for
both TAVI and SAVR
Apply treatment specific mortality
for TAVI (0.24) and SAVR (0.25)
Holding other base-case assumptions
constant
$870,143/LY
Dominated
$79,110/LY
$657,237/QALY
$65,858/LY
$289,298/QALY
No new cases of stroke, MI, or AKI
beyond 1 y
$192,431/LY
Dominated
$84,963/LY
$358,066/QALY
$64,529/LY
$173,413/QALY
10-y time horizon while holding other
base-case assumptions constant
$398,576/LY
Dominated
$86,254/LY
$897,984/QALY
$71,137/LY
$333,532/QALY
No new cases of stroke, MI, or AKI
beyond 1 y, with 10-y time horizon
$169,258/LY
Dominated
$89,725/LY
$393,488/QALY
$68,318/LY
$187,765/QALY
TF-TAVI, Transfemoral transcatheter aortic valve implantation; SM, standard management; LY, life-year; QALY, quality-adjusted life-year;MI, myocardial infarction; AKI, acute
kidney injury; TA, transapical; SAVR, surgical aortic valve replacement.
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0.116 at aWTP threshold of $49,000 per LY/QALY, respec-
tively, and increased to 0.375 and 0.131 at a WTP threshold
of $150,000 per LY/QALY, respectively (Figure 3,
C and D).
DISCUSSION
This model-based economic evaluation compared the in-
cremental cost-effectiveness of TF-TAVI with SM in inop-
erable patients with SSAS, resulting in ICERs relatively
favorable for TAVI given the commonly accepted WTP
threshold (eg, $50,000/QALY). In contrast, the ICER of
TAVI (TF or TA) compared with SAVR in operable patients
with SSAS was large, suggesting that TAVI may not be
a cost-effective treatment option for this patient population.
The differences in the cost of TAVI between the 2 analy-
ses are largely attributable to the larger rates of stroke and
rehospitalization in the long-term for the inoperable patient
population. Only a small difference in total LYs for TAVI
between the 2 analyses was observed, with operable pa-
tients gaining approximately 0.06 more LYs compared
with inoperable patients over the 20-year time horizon.
There are a number of strengths to this economic evalu-
ation. Key clinical model parameters for all 4 treatments
were derived from the published PARTNER trial cohorts.5,7
Cost variables used in the model were all based on CanadianThe Journal of Thoracic and Csources, including a recent costing analysis of TAVI.11 Un-
certainty surrounding both the model parameters and the
model structure was incorporated and assessed using a com-
prehensive DSA, a PSA, and various scenario analyses.
There are currently 2 published studies in the literature
analyzing the cost-effectiveness of TAVI.21,22 Watt and
colleagues22 published a study assessing the cost-
effectiveness of TAVI compared with medical management
in patients with severe AS who are ineligible for SAVR
from the perspective of the UK National Health Service.
This analysis estimated a base-case ICER of £16,100/
QALY using a decision analytic model over a 10-year
time horizon. The model structure presented by Watt and
colleagues differed in that it was based on patients moving
from different hospital wards, a rehabilitation center, home
and death in the short-term, and home, reoperation, and
death in the long-term. Although similar operative compli-
cations were included in the model from PARTNER-B,
long-term complication rates were absent. As was observed
in the scenario analysis presented in our analysis, removal
of long-term cases of stroke, MI, and AKI resulted in
more favorable ICERs. In addition, all costing and hospital
length of stay values were based on UK sources, which may
not be applicable to the Canadian context. Despite these dif-
ferences, the overall results of the 2 analyses seem to be in
agreement that TF-TAVI represents cost-effective use ofardiovascular Surgery c Volume 146, Number 1 57
FIGURE 3. A, Cost-effectiveness acceptability curves for TF-TAVI versus SM (LYs). B, Cost-effectiveness acceptability curves for TF-TAVI versus SM
(QALYs). C, Cost-effectiveness acceptability curves for TF or TA-TAVI versus SAVR (LYs). D, Cost-effectiveness acceptability curves for TF or TA-TAVI
versus SAVR (QALYs). TF-TAVI, Transfemoral transcatheter aortic valve implantation; TA-TAVI, transapical transcatheter aortic valve implantation; SM,
standard management; SAVR, surgical aortic valve replacement; LY, life-year; QALY, quality-adjusted life-year; Can$, Canadian dollars.
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commonly accepted WTP thresholds.
A recent Health Technology Assessment report pub-
lished by the Belgian Health Care Knowledge Centre also
presents 2 analyses of the cost-effectiveness of TAVI in
both a nonoperable and high-risk operable patient popula-
tion from the perspective of the Belgian health care payer.21
Cohort A (ie, high-risk operable patients) analysis resulted
in a base case of V759,072/LY and V749,416/QALY when
comparing TAVI (TF and TA) and SAVR, respectively, us-
ing only a 1-year time horizon. The choice of time horizon
was justified on the basis that the PARTNER-A trial did not
show a significant difference in mortality between TAVI and
SAVR. Furthermore, this report assumed that utility values
for the cohort A analysis were similar as those reported for
cohort B using the EuroQol 5 dimensions. The SAVR util-
ities were also assumed to be similar to the cohort B TAVI
values with an arbitrary 0.1 decrement applied during the
first month. This approach may be flawed, because most cli-
nicians would differentiate these 2 patient populations and
may account for the slight difference in results observed.
However, inspection of the baseline patient characteristics58 The Journal of Thoracic and Cardiovascular Surgeof cohorts A and B finds them to be fairly similar except
for differences in the proportions of men/women and frailty.
The cohort B (ie, inoperable patients) analysis in the Bel-
gian Health Technology Assessment resulted in a base case
of V31,856/LY and V37,432/QALY when comparing TF-
TAVI and a nonsurgical approach over a lifetime horizon,
respectively (almost equivalent to our 20-year time horizon
for this patient population). When accounting for differ-
ences in currency the LYs, ICER is slightly higher than re-
ported in our analysis. This may be explained by the direct
use of cumulative mortality rates from the PARTNER trial
in the Belgian analysis at 1 year (31% and 50% for TF-
TAVI and SM, respectively). To avoid double counting,
our analysis removed the patients who died at 30 days after
operation, and therefore a larger difference in the mortality
rates was used in our analysis (27% and 48% for TF-TAVI
and SM, respectively). EuroQol 5 dimension utility scores
were also used to determine the total QALYs in the Belgian
analysis, in contrast to using the proportion of NYHA clas-
ses. Despite these differences, the results from the 2 analy-
ses are consistent with the results presented in our study and
concluded that TF-TAVI represents cost-effective use ofry c July 2013
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Dresources in inoperable patients with SSAS, whereas the use
of TAVI in an operable patient population compared with
SAVR does not seem to be a cost-effective use of resources.
Study Limitations
This study has a few key limitations. Most important is
the reliance of both the primary and secondary analyses
on the PARTNER trial cohorts. As with all randomized con-
trolled trials, the PARTNER trial has a specific predefined
patient population and a limited follow-up period, which
makes it difficult to know for certain whether the trial re-
sults and therefore the results of this analysis will be indic-
ative of real-world clinical practice in Canada. Post-market
registries in Europe may provide evidence for patients not
eligible for the PARTNER trial and therefore may provide
greater insight into real-world effectiveness. The results
suggest that TAVI is feasible and operative outcomes are ac-
ceptable, but improvements in technical efficiency and
postoperative care are essential to reducing operative mor-
tality.23 The registries have also noted a relationship be-
tween aortic regurgitation and mortality in the long-term
for the CoreValve prosthesis (Medtronic Inc, Minneapolis,
Minn); however, this evidence has not been extensively
measured in the registries limited to the SAPIEN valve.23,24
Because effectiveness and cost-effectiveness can vary be-
tween jurisdictions and populations slightly different than
the PARTNER cohorts may receive TAVI in clinical prac-
tice, it may be necessary to reduce decision uncertainty or
identify optimal patient populations through the use of lo-
cally conducted field evaluations.25
Various assumptions were also made in the 2 analyses.
Clinical event rates (stroke, MI, and AKI) were assumed
to remain constant after year 1 of the model. Scenario anal-
yses were conducted to address this uncertainty, and re-
moval of these events resulted in more favorable
estimates of cost-effectiveness. The rates of temporary
and permanent dialysis were also assumed to be the same
for all 4 treatments because of the lack of appropriate
data. One-way DSAs showed that changes in these values
over their 95% CIs had only modest effects ($2,000/LY
or QALY) on the overall estimates of cost-effectiveness
for both analyses. In addition, the procedural cost of
SAVR was derived from patients aged more than 70 years,
which may be an underestimate of the costs of patients from
cohort A of the PARTNER trial (more severe disease and
average age of 84 years). Despite this assumption, model re-
sults for the secondary analysis were fairly robust to
changes in this parameter. Results remained consistent
with the base-case values during 1-way DSA. An alternative
value for the procedural cost of SAVR ($42,298) from the
‘‘atypical cases’’ of CMG Grouper 165 from the OCCI10
was also tested. However, results remained unfavorable
for TAVI (TF or TA), with ICERs of $127,888/LY and
TAVI remaining dominated for the QALY comparison.The Journal of Thoracic and CThis economic evaluation is also specific for the Edwards
SAPIEN heart valve system (Edwards Lifesciences), and
estimates of cost-effectiveness may not be applicable to
other available or next generation devices (ie, CoreValve
Revalving System, Medtronic Inc).CONCLUSIONS
From a Canadian reimbursement perspective, this
economic evaluation suggested that TF-TAVI was a cost-
effective option for inoperable patients with SSAS in com-
parison with SM. However, TAVI (TF or TA) may not be
a cost-effective treatment for operable patients with SSAS
compared with SAVR. Given the uncertainty in the long-
term data, it is important to collect more local evidence
through the use of conditionally funded field evaluations
to confirm current estimates of effectiveness and cost-
effectiveness in Ontario.References
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TABLE E1. Additional procedural, 30-day postoperative, and long-term model inputs (mean [a, b])
Model variable
Inoperable patients Operable patients
TF-TAVI Reference SM Reference TF or TA-TAVI Reference SAVR Reference
Late event probabilities (all beta distributions)
Mortality
After stroke first year 0.181 (526, 2379) E1
After stroke
subsequent years
0.10 (90, 809) E1
After MI 0.477 (1189, 1304) E2
After AKI 0.35 (796, 1478) E3
Hospitalization and long-term care facility stays (gamma distributions for costs, beta distributions for probabilities)
Length of hospital stay
after procedure (d)
11 (22, 0.5) E4 11 (31, 0.36) E5 11 (22, 0.5) E4 36 (15, 2) E6
Probability
rehospitalization (30 d)
0.056 (10,169) E7 0.10 (18, 161) E7 0.043 (15, 333) E8 0.034 (12, 339) E8
Probability
rehospitalization
(1 y)
0.223 (40, 139) E7 0.441 (79, 100) E7 0.167 (58, 290) E8 0.128 (45, 306) E8
Length of stay after
rehospitalization (d)
16 (157, 0.102) E9
Probability of long-term
care facility stay
0.512 (21, 20) E10
Length of long-term care
facility stay (d)
16 (157, 0.102) E9
Cost of long-term care
facility stay
155 (16, 9.7) E11
Cost of complications (all gamma distributions)
Endocarditis 19,913 (8, 2388) E12
Vascular complications 5342 (46, 116) E12
Pacemaker implantation 13,039 (369, 35) E12
Paravalvular leaks 25,302 (19, 1364) E12
Major bleeding 3040 (26, 116) E12
Atrial fibrillation 7773 (76, 102) E12
Temporary disability 1669 (127, 13) E13
Permanent disability 12,996 (31, 424) E13
MI 10,949 (91, 120) E12
Temporary dialysis 5368 (47, 114) E14
Permanent dialysis 15,780 (16, 986) E14
Cost of long-term health states (all gamma distributions)
Temporary disability
(first year)
10,925 (16, 683) E13
Permanent disability
(first year)
37,163 (16, 2323) E13
Stroke subsequent years 7994 (16, 500) E15
MI first year 3116 (177, 18) E16
MI subsequent years 1870 (16, 117) E17
Temporary dialysis 11,192 (16, 700) E14
Permanent dialysis 73,273 (16, 4580) E14
Baseline utility weights (all beta distributions)
NYHA class I 0.855 (4511, 765) E18
NYHA class II 0.771 (5229, 1553) E18
NYHA class III 0.673 (3641, 1769) E18
NYHA class IV 0.532 (188, 165) E18
(Continued)
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TABLE E1. Continued
Model variable
Inoperable patients Operable patients
TF-TAVI Reference SM Reference TF or TA-TAVI Reference SAVR Reference
Utility weights (all beta distributions)
Alive without
complications
0.988 (56, 0.69) E19
Endocarditis 0.9 (4, 0.5) E20
Vascular complications 0.981 (2809, 54) E21
Pacemaker implantation 0.76 (23, 7) E22
Paravalvular leaks 0.9 (32, 4) E23
Major bleeding 0.87 (38, 6) E24
Atrial fibrillation 0.95 (17, 0.9) E25
Temporary disability 0.75 (14, 5) E26
Permanent disability 0.45 (246, 301) E27
MI first year 0.8 (50, 13) E28
MI subsequent years 0.95 (17, 0.9) E28
Temporary dialysis 0.84 (102, 19) E29
Permanent dialysis 0.58 (180, 130) E30
TF-TAVI, Transfemoral transcatheter aortic valve implantation; SM, standard management; TA-TAVI, transapical transcatheter aortic valve implantation; SAVR, surgical aortic
valve replacement; MI, myocardial infarction; AKI, acute kidney injury; NYHA, New York Heart Association.
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